Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.24 USD | +3.04% | +0.23% | -11.73% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
Evolution of the average Target Price on UroGen Pharma Ltd.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering UroGen Pharma Ltd.
Oppenheimer | |
HC Wainwright | |
Goldman Sachs | |
Jefferies & Co. | |
Berenberg Bank |
EPS Revisions
- Stock Market
- Equities
- URGN Stock
- Consensus UroGen Pharma Ltd.